Jupiter Topco LLC Makes New Investment in Lantheus Holdings, Inc. $LNTH

Jupiter Topco LLC purchased a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 5,188,416 shares of the medical equipment provider’s stock, valued at approximately $575,628,000. Jupiter Topco LLC owned approximately 7.95% of Lantheus at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Western Wealth Management LLC purchased a new position in shares of Lantheus during the 1st quarter valued at $25,000. Smartleaf Asset Management LLC raised its holdings in Lantheus by 63.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after acquiring an additional 197 shares during the period. Parallel Advisors LLC raised its holdings in Lantheus by 122.6% during the fourth quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock valued at $36,000 after acquiring an additional 298 shares during the period. Osterweis Capital Management Inc. purchased a new position in shares of Lantheus in the second quarter valued at about $36,000. Finally, Bessemer Group Inc. lifted its position in shares of Lantheus by 221.2% in the first quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 354 shares in the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Stock Performance

NASDAQ LNTH opened at $100.87 on Wednesday. The stock has a market capitalization of $6.58 billion, a PE ratio of 24.36 and a beta of -0.03. The business has a 50 day simple moving average of $103.92 and a two-hundred day simple moving average of $91.01. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.06 and a quick ratio of 2.89. Lantheus Holdings, Inc. has a 1-year low of $49.67 and a 1-year high of $111.86.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.30 by $0.25. The business had revenue of $388.18 million for the quarter, compared to the consensus estimate of $363.23 million. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.The company’s revenue was up 2.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.57 EPS. On average, research analysts predict that Lantheus Holdings, Inc. will post 4.48 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently issued reports on LNTH shares. Weiss Ratings cut Lantheus from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, August 13th. CJS Securities cut Lantheus from a “market outperform” rating to a “market perform” rating in a report on Tuesday, August 4th. Citigroup restated an “outperform” rating on shares of Lantheus in a research note on Friday, May 8th. William Blair set a $102.50 price objective on shares of Lantheus in a research report on Monday, August 3rd. Finally, Truist Financial lowered shares of Lantheus from a “buy” rating to a “hold” rating and dropped their target price for the stock from $125.00 to $102.50 in a research report on Monday, August 3rd. Four analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat.com, Lantheus presently has an average rating of “Hold” and a consensus price target of $108.11.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.